In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cubist gets US co-promotion rights to Optimer's Dificid

Executive Summary

Anti-infectives developer Optimer Pharmaceuticals Inc. has licensed Cubist Pharmaceuticals Inc. (therapies for the acute care market) exclusive US co-promotion rights to its Dificid (fidaxomicin) antibiotic for the treatment of Clostridium difficile infection (CDI) or C. difficile-associated diarrhea (CDAD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Intra-Biotech Deal
    • Marketing (Licensing)

Related Companies